Skip to main content

Big Pharma backs CMV vaccine

Swiss pharmaceutical giant Novartis has teamed up with an American biotech company to develop the first commercial vaccine for cytomegalovirus (CMV), which kills or disables tens of thousands of infants every year. Because CMV infection does not usually lead to detectable symptoms in otherwise healthy people, only a handful of researchers have endeavored to develop a CMV vaccine. In fact, the virus is one of the top causes of birth defects; a 1999 National Academy of Sciences report estimated t

Written byBob Grant
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Swiss pharmaceutical giant Novartis has teamed up with an American biotech company to develop the first commercial vaccine for cytomegalovirus (CMV), which kills or disables tens of thousands of infants every year. Because CMV infection does not usually lead to detectable symptoms in otherwise healthy people, only a handful of researchers have endeavored to develop a CMV vaccine. In fact, the virus is one of the top causes of birth defects; a 1999 National Academy of Sciences report estimated that CMV costs the US as much as $4.4 billion per year. (See our 2006 article on linkurl:CMV vaccine;https://www.the-scientist.com/article/display/36883/ development efforts). The vaccine candidate, AVX601, was created by scientists at North Carolina-based AlphaVax and has fared well in a linkurl:phase I clinical trial;https://www.alphavax.com/docs/news/news_25.pdf on healthy adults. AVX601 is a single-cycle particle vaccine that carries RNA encoding three antigens--phosphoprotein 65, immediate early protein I, and glycoprotein B--from the CMV virus, and the vaccine was shown to raise levels of neutralizing antibodies and antigen-specific T cells in phase I trial subjects. Now that it has licensed the technology, Novartis will marshal the compound through phase II trials, which are slated to commence sometime this year, according to a linkurl:statement;https://www.novartis.com/newsroom/media-releases/en/2008/1279693.shtml from the company. Janice Kimpel, AlphaVax's vice president of business development, told __The Scientist__ that Novartis plans to develop the vaccine to target adolescent women before they become pregnant and pass CMV on to their unborn children. According to a statement from Novartis, the company paid $20 million (USD) for the rights to AphaVax's CMV vaccine program. Under the deal, Novartis also has an option to make an equity investment of four millions shares at the end of phase II clinical trials. AlphaVax will get milestones and royalties.
**__Related stories:__***linkurl:A Long Shot on Cytomegalovirus;https://www.the-scientist.com/article/display/36883/
[December 2006]*linkurl:Cytomegalovirus cell receptor;https://www.the-scientist.com/article/display/21486/
[24 July 2003]
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
November digest cover
November 2026

Chemistry Meets Arcade Combat in “Reaction Rumble” Game

Choose your fighter! Enter the arena as chemical elements and dole out moves inspired by real-world reactions in this educational browser-based game.

View this Issue
From Pilot to Practice: Advancing Regulatory Reliance

From Pilot to Precedent: A Year of Regulatory Innovation through PRISM and What it Means for Cloud Adoption in Regulatory Submissions

DNAnexus
Thumbnail

Make It Local, Make It Last: The Evolution of mRNA Protein Replacement Therapy

Improving Western Blot Analysis of Biofluid Samples

Improving Western Blot Analysis of Biofluid Samples

Bio-Rad
Reducing AAV Sample Consumption With Multiwavelength SV-AUC

Reducing AAV Sample Consumption With Multiwavelength SV-AUC

​Beckman Coulter

Products

Sino Biological Logo

Sino Biological Advances AI-Designed Molecule Validation with 4RISE™

Abstract image of circles and concentric lines on a blue and pink background.

MX Analytical and Precision Balances: Effortless Weighing and Secure Data Handling

Mettler
3D multicolored conceptual image of antibody molecules

Premium BsAb: LC-MS-Assisted Bispecific Antibody Production with >98% Heterodimer Purity

WuXi Biologics
Abstract conceptual image of AI technology for medical science research.

Exploring a New Era of Pharmaceutical Innovation